SeriesBabylon 5, a science fiction television series
The number 5 features in the television series Battlestar Galactica in regards to the Final Five cylons and the Temple of Five
Hi-5 (Australian TV series), a television series from Australia
Hi-5 (UK TV series), a television show from the United Kingdom
Hi-5 Philippines a television show from the Philippines
Odyssey 5, a 2002 science fiction television series
Tillbaka till Vintergatan, a Swedish childrens television series featuring a character named "Femman" (meaning five), who can only utter the word five. The Five (talk show): Fox News Channel roundtable current events television show, premiered 2011, so-named for its panel of five commentators. Yes! PreCure 5 is a 2007 anime series which follows the adventures of Nozomi and her friends. It is also followed by the 2008 sequel Yes! Pretty Cure 5 GoGo! The Quintessential Quintuplets is a 2019 slice of life romance anime series which follows the everyday life of five identical quintuplets and their interactions with their tutor. It has two seasons, and a final movie is scheduled in summer 2022. Hawaii Five-0, CBS American TV series.
Based on these additional studies, the FDA granted in 2016 full approval and updated the label to include patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia for whom no other tyrosine kinase inhibitor therapy is indicated. Approval was also granted for T315I-positive and T315I-positive Philadelphia chromosome positive acute lymphoblastic leukemia. Adverse effects
The United States Food and Drug Administration issued a partial clinical hold on new trial enrollment for ponatinib on October 9, 2013, due to an increased number of blood clots observed in patients taking the drug. The EPIC trial was later canceled on October 18. Subsequent studies of 449 patients treated during 4 years with ponatinib for chronic phase chronic myelogenous leukemia found the following adverse reactions. 150 Patients experienced cardiac vascular (21% of patients), peripheral vascular (12%), and cerebrovascular (9%) arterial occlusive events. Venous thromboembolic events occurred in 6% of patients. The most common all-grade adverse events included hypertension (69%), rash (63%), abdominal pain (48%), fatigue (47%), headache (43%), arterial ischemia (42%), dry skin (42%), constipation (41%), arthralgia (32%), nausea (28%), pyrexia (26%), peripheral neuropathy (24%), myalgia (24%), pain in extremity (23%), back pain (21%), and diarrhea (20%). In addition, there have been reported cases of the posterior reversible encephalopathy syndrome. Recently, an analogue of ponatinib was developed that retained anti-tumor efficacy but had reduced cardiovascular toxicity in experimental models.